(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of 74.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Alumis's revenue in 2026 is $22,121,000.On average, 10 Wall Street analysts forecast ALMS's revenue for 2026 to be $571,031,914, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $1,414,008,644. On average, 8 Wall Street analysts forecast ALMS's revenue for 2027 to be $2,988,783,128, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $6,576,784,389.
In 2028, ALMS is forecast to generate $14,186,019,534 in revenue, with the lowest revenue forecast at $5,964,412,687 and the highest revenue forecast at $21,418,394,494.